<DOC>
	<DOC>NCT00370071</DOC>
	<brief_summary>The purpose of this study is to determine if the study drug is effective and safe in the treatment of Multiple Sclerosis (MS) in patients of Chinese origin.</brief_summary>
	<brief_title>Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250Âµg in Patients of Chinese Origin With Multiple Sclerosis</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany. Bayer HealthCare AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Chinese origin diagnosis of Relapsing remitting multiple sclerosis or secondary progressive multiple sclerosis Any disease other than Multiple Sclerosis (MS) that could better explain the patients signs and symptoms HIV (human immunodeficiency virus) infections Hepatitis A Syphilis immunodeficiency rheumatic disease or Sjogren syndrome heart disease severe depression pregnancy or lactation conditions interfering with Magnetic Resonance Imaging (MRI) Gadolinium DTPA (Gadovist, contrast agent) allergy allergy against human proteins, paracetamol, acetaminophen and ibuprofen intolerance participation in other trial</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>MS</keyword>
</DOC>